Paul Szabolcs, MD

Articles by Paul Szabolcs, MD

Rapid Readout: HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB Transplantation

February 10th 2022

Expert hematologist/oncologist Paul Szabolcs, MD, reviews positive data from a clinical trial comparing hematopoietic stem cell transplantation and omidubicel with standard cord blood transplantation.

Latest Updated Articles

Paul Szabolcs, MD

Articles by Paul Szabolcs, MD

Rapid Readout: HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB Transplantation

Latest Updated Articles

Trending on OncLive

FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC

Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC

SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma

HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts

Hematology Experts Preview Key Abstracts to Watch at the 2026 Transplantation & Cellular Therapy Meetings